Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T67909 |
TAK1 inhibitor
compound 13a |
Topoisomerase | DNA Damage/DNA Repair |
TAK1 inhibitor 是一种抑制剂,对MCF-7、A549 、DU-145 、MDA MB-231有抑制作用,IC50分别为 0.021、0.14、0.064 、0.19 。化合物13 具有较好的抑菌活性,麦克风范围为93.7 ~ 46.9μg / mL,麦克风范围为7.8 ~ 5.8μg / mL。 | |||
T61977 |
FLT3/D835Y-IN-1
|
||
FLT3/D835Y-IN-1 (化合物13a) 是一种选择性的、口服活性的FLT3和FLT3/D835Y 抑制剂,IC50分别为 0.26 nM 和 0.18 nM。FLT3/D835Y-IN-1 具有抗癌作用,可以用于急性髓系白血病的研究。 | |||
T63110 |
CBP/p300-IN-15
|
||
CBP/p300-IN-15 (compound 13a) 是一种有效的 p300 (IC50: 2.5 nM) 和 CBP (IC50: 28.0 nM) 抑制剂。CBP/p300-IN-15 能够较好的抑制 OVCAR-3 细胞 (EC50: 0.865 μM) 和 A2780 细胞 (EC50: 2.71 μM)。 CBP/p300-IN-15 能够用于研究卵巢癌。 | |||
T78766 | HDAC-IN-59 | HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDAC-IN-59(compound 13a)为一种高效HDAC抑制剂。该化合物能增强细胞内ROS生成,导致DNA损伤,阻止G2/M期细胞周期进程,并激活线粒体途径引发细胞凋亡。 | |||
T62458 | EGFR-IN-56 | ||
EGFR-IN-56 (Compound 13a) 是一种 EGFR 的有效抑制剂,能够作用于 EGFRT790M (IC50: 541.7 nM) 和 EGFRT790M/L858R (IC50: 132.1 nM)。EGFR-IN-56 能够将癌细胞的细胞周期阻滞在 G2/M 期,并诱导细胞凋亡 (apoptosis)。 | |||
T79540 |
hCA/VEGFR-2-IN-1
|
Carbonic Anhydrase | Metabolism |
hCA/VEGFR-2-IN-1 是一种高效的双靶点抑制剂,对 hCA IX 和 hCA XII 两种碳酸酐酶(CA)具有极低的Ki值,分别为8.3 nM和4.7 nM。同时,hCA/VEGFR-2-IN-1 也是一种有效的 VEGFR-2 抑制剂,其 IC50 值仅为26.3 nM,并且显示出抗癌活性。 | |||
T38446 |
ROC-0929
|
||
ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s), effectively targeting hGX with an IC50 of 80 nM. It efficiently inhibits the phosphorylation of ERK1/2 and p-38. sPLA2s, belonging to the disulfide-rich, Ca2+-dependent enzyme family, catalyze the hydrolysis of glycero-phospholipids at the sn-2 position, resulting in the release of a fatty acid and a lysophospholipid. ROC-0929 holds promise in researching inflammation-related diseases. |